# US 2019/0166810 A1 · Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0166810 A1
- Document ID: US20190166810A1
- Status: Published application
- Kind: A1
- Application number: 16/309,871
- Filed: 2017-06-27
- Published: 2019-06-06
- Earliest claimed: 2016-06-27
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Karl-Dimiter BISSIG; Maria de las Mercedes Barzi DIEGUEZ; Peter Francis PANKOWICZ
- Web page: https://patentgrep.com/patent/US20190166810A1

## CPC

- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A01K 67/0276: Knock-out vertebrates
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A01K 2207/15: Humanized animals
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.

## Claims

### Claim 1

A method for preparing a chimeric non-human animal comprising human hepatocytes, the method comprising:
(a) providing a non-human animal comprising a reduction or deletion of NADPH-P450 oxidoreductase (Por) gene resulting in reduced or absent expression of Por protein; and
(b) transplanting human hepatocytes into the non-human animal.

### Claim 2 (depends on 1)

The method of claim 1, wherein providing the non-human animal comprises reducing or deleting the Por gene resulting in reduced or absent expression of Por protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reduced or deleted Por gene is a conditional knockdown or knockout of the Por gene.

### Claim 4 (depends on 1)

The method of claim 1, wherein the reduced or deleted Por gene is the result of a mutation, a transgene, treatment with an exogenous substance or somatic genome engineering.

### Claim 5 (depends on 4)

The method of claim 4, wherein the somatic genome engineering comprises Guide RNA (gRNA) and Caspase 9.

### Claim 6 (depends on 1)

The method of claim 1, wherein the non-human animal comprises a floxed allele of the Por gene, and wherein the non-human animal is provided with a Cre recombinase sufficient to produce a conditional knockout of the Por gene.

### Claim 7 (depends on 6)

The method of claim 6, wherein the non-human animal comprising the floxed allele of the Por gene is provided with at least a first dose of a virus that encodes Cre recombinase.

### Claim 8 (depends on 7)

The method of claim 7, wherein the non-human animal is provided with at least a second dose of a virus that encodes Cre recombinase.

### Claim 9 (depends on 1)

The method of claim 1, comprising (a) providing a non-human animal comprising a floxed allele of the Por gene with a first does of a virus that encodes Cre recombinase;
(b) transplanting human hepatocytes into the non-human animal; and
(c) providing the non-human animal with a second dose of a virus that encodes Cre recombinase.

### Claim 10 (depends on 9)

The method of claim 9, wherein steps (a) and (b) occur sequentially.

### Claim 11 (depends on 9)

The method of claim 9, wherein steps (a) and (b) occur simultaneously.

### Claim 12 (depends on 7)

The method of claim 7, wherein the non-human animal comprising the floxed allele of the Por gene is crossed with a transgenic non-human animal strain expressing Cre recombinase.

### Claim 13 (depends on 1)

The method of claim 1, wherein the non-human animal further comprises a reduction or deletion of at least one additional gene encoding an enzyme involved in drug metabolism.

### Claim 14 (depends on 13)

The method of claim 13, wherein the at least one additional enzyme is a phase II drug enzyme.

### Claim 15 (depends on 1)

The method of claim 1, wherein the non-human animal further comprises a reduction or deletion of UDP-glucose 6-dehydrogenase (UGDH) gene.

### Claim 16 (depends on 1)

The method of claim 1, wherein the non-human animal further comprises a reduction or deletion of Glutathione synthetase (GSS) gene.

### Claim 17 (depends on 1)

The method of claim 1, wherein the non-human animal is selected from the group consisting of primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep and pig.

### Claim 18 (depends on 1)

The method of claim 1, wherein the non-human animal is a mouse.

### Claim 19 (depends on 1)

The method of claim 1, wherein the non-human animal is selected from the group consisting of (i) the FRG (Fah−/−/Rag2−/−/Il2rg−/−) non-human animal, (ii) a transgenic urokinase type plasminogen activator (uPA) non-human animal, which overexpress uPA under an inducible promoter, preferably a liver-restricted albumin promoter, (iii) the thymidine kinase-NOD/Shi-scid/IL-2Rγnull (TK-NOG) non-human animal, which is a immunodeficient NOG non-human animal with transgenic expression of thymidine kinase under control of liver-restricted promoter, (iv) a non-human animal expressing an inducible Caspase 8 in the liver, and (v) a non-human animal expressing an inducible Caspase 9 in the liver.

### Claim 20 (depends on 1)

A chimeric non-human animal, offspring thereof, or a portion thereof, which has a chimeric liver comprising human hepatocytes, prepared by the method according to claim 1.

### Claim 21 (depends on 20)

The chimeric non-human animal of claim 20, wherein the non-human animal is selected from the group consisting of primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep and pig.

### Claim 22 (depends on 20)

The chimeric non-human animal of claim 20, wherein the non-human animal is a mouse.

### Claim 23 (depends on 20)

The chimeric non-human animal of claim 20, wherein chimeric non-human animal substantially lacks autogenous hepatocytes.

### Claim 24 (depends on 20)

The chimeric non-human animal of claim 20, wherein human hepatocytes account for at least 60% of all hepatocytes in the chimeric liver.

### Claim 25 (depends on 20)

The chimeric non-human animal of claim 20, wherein human hepatocytes account for at least 70% of all hepatocytes in the chimeric liver.

### Claim 26 (depends on 20)

The chimeric non-human animal of claim 20, wherein human hepatocytes account for at least 80% of all hepatocytes in the chimeric liver.

### Claim 27 (depends on 20)

The chimeric non-human animal of claim 20, wherein human hepatocytes account for at least 90% of all hepatocytes in the chimeric liver.

### Claim 28 (depends on 20)

The chimeric non-human animal of claim 20, wherein the chimeric non-human animal is immunodeficient.

### Claim 29 (depends on 20)

A method for screening for a substance that affects human liver functions, comprising:
(a) administering a test substance to the chimeric non-human animal of claim 20;
(b) measuring one or more values in the chimeric non-human animal to which the test substance is administered in (a); and
(c) selecting a test substance that causes an increase or decrease in one or more values measured in (b), compared with the one or more values measured in a chimeric non-human animal to which no test substance is administered.

### Claim 30 (depends on 29)

The method of claim 29, wherein the one or more values is selected from the group consisting of a metabolite of the test substance, human albumin concentration, body weight curve, liver-weight-to-body-weight ratio, total albumin level, total protein level, Alanine Aminotransferase (ALT) level, Aspartate Aminotransferase (AST) level, and total bilirubin level, creatinine, Blood Urea Nitrogen (BUN), troponine, blood count, TSH and histological assessment for pathologies in the human and non-human organs.

### Claim 31 (depends on 20)

A method for evaluating the toxicity of a test substance against human hepatocytes and any other non-human organ in the non-human chimeric animal, comprising:
(a) administering a test substance to the chimeric non-human animal of claim 20;
(b) measuring one or more indicators in the chimeric non-human animal to which the test substance is administered in (a); and
(c) evaluating the effect of the test substance on human hepatocytes using, one or more indicators measured in (b), compared with the one or more indicators measured in a chimeric non-human animal to which no test substance is administered.

### Claim 32 (depends on 31)

The method of claim 31, wherein the one or more indicators is selected from the group consisting of an increase or a decrease in any one or more of a metabolite of the test substance, human albumin concentration, body weight curve, liver-weight-to-body-weight ratio, total albumin level, total protein level, ALT level, AST level, and total bilirubin level, creatinine, BUN, troponine, blood count and TSH as well as histological alterations including but not limited to necrosis and apoptosis in the human and non-human organs.
